Skip to main
SER
SER logo

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc. is well-positioned for future growth, particularly with its pipeline candidate SER-270, which has the potential to drive significant long-term upside beyond current forecasts. The company’s innovative POZ Platform delivery technology enhances drug precision and addresses the limitations of existing biocompatible polymers, increasing the attractiveness of its product candidates. Additionally, the expanding approval landscape for the enFuse delivery system indicates a favorable trajectory for SER-252, bolstering the overall positive outlook for the company's future performance.

Bears say

Serina Therapeutics reported a consistent net loss of $0.64 per share, raising concerns about its financial sustainability amidst ongoing development efforts. The company faces several risks, including potential delays in advancing its lead drug candidate, SER-252, through clinical assessment, as well as challenges in securing regulatory approval and commercial success due to competitive pressures. Furthermore, the downward revision of the company's full-year 2025 net loss forecast to $2.01 per share, up from an initial estimate of $0.36, highlights deteriorating financial prospects and increasing risks of dilution.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.